RxDoctor Payments Data

Mary McKinley, MD

Internal Medicine · Macon, GANPI 1023003993

Payments from drug & device makers

$10,063in general payments, 2019–2025

Across 610 payments — averaging $16.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AstraZeneca$1K
  • AbbVie$661
  • Pfizer$656
  • Amgen$507
  • Lilly USA, LLC$478
  • plus $5K from 46 others

What the payments were for

  • Food & beverage$9,77797%
  • Education$2262%
  • Gifts$591%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$10,063 in reported general payments places this provider in the 90th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$757,545
Medicare patients
845
Services billed
12,036

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban787$324,509
OzempicSemaglutide251$292,701
JardianceEmpagliflozin299$243,944
MounjaroTirzepatide173$199,233
JanuviaSitagliptin Phosphate158$137,810
FarxigaDapagliflozin Propanediol128$111,251
TrulicityDulaglutide124$97,304
XareltoRivaroxaban173$86,530
EntrestoSacubitril/Valsartan165$73,871
MyrbetriqMirabegron222$65,371
RybelsusSemaglutide37$57,626
LinzessLinaclotide74$53,312
VascepaIcosapent Ethyl76$51,603
Tresiba Flextouch U-100Insulin Degludec73$42,168
Trelegy ElliptaFluticasone/Umeclidin/Vilanter52$36,048

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,384$350,327288 claims
PfizerEliquis$656$324,509787 claims
Lilly USA, LLCMounjaro, Trulicity$478$296,537297 claims
Boehringer IngelheimJardiance, Tradjenta$441$267,308335 claims
MerckJanuvia, Belsomra, Janumet$380$192,795231 claims
AstraZenecaFarxiga, Breztri Aerosphere, Brilinta, Symbicort$1,100$171,605239 claims
Johnson & JohnsonXarelto, Risperdal Consta$207$118,365199 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$244$85,847140 claims
NovartisEntresto$253$73,871165 claims
AbbVieLinzess, Qulipta$661$69,44889 claims
Astellas Pharma US IncMyrbetriq$340$65,371222 claims
Otsuka America Pharmaceutical, Inc.Rexulti$48$24,21727 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Macon

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →